Jordan Aday
Clinical Researcher
Data updated
Papers
Trials
Research Footprint
Jordan Aday appears in 13 tracked papers (2020–2026), most studied alongside Psilocybin, Ayahuasca and LSD, across Depressive Disorders, Personality & Trait Factors and Substance Use Disorders (SUD).
Most-cited paper: Long-term effects of psychedelic drugs: A systematic review (253 citations).
Frequent co-authors: Joshua Woolley, Emily Bloesch and Christopher Davoli.
Publication Landscape
How the 13 papers Blossom tracks for Jordan Aday line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Jordan Aday's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 13 of 13 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Jordan Aday publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Jordan Aday publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Jordan S. Aday (J. S. Aday) is a clinical researcher whose work focuses on naturalistic and survey-based investigations of psychedelic use, with particular emphasis on ayahuasca ceremonies, user attitudes, and the downstream psychological and social effects of psychedelic experiences. Aday has contributed to prospective naturalistic studies examining outcomes such as gratitude, connectedness to nature, and changes in aesthetic experience following ayahuasca use, and has led retrospective and cross-sectional surveys probing major life changes associated with naturalistic psychedelic use.
Beyond outcome measurement, Aday has examined pragmatic and ethical issues in contemporary psychedelic practice, including users' attitudes toward treatment costs and the appeal of non-hallucinogenic alternatives, and has documented the prevalence of personal psychedelic use among therapists — work that bears on training, clinical standards and research generalisability. Methodologically, Aday's contributions emphasise ecologically valid designs, participant-reported outcomes, and the implications of naturalistic data for clinical translation and policy debates in psychedelic medicine.
Key Impact
Notable for conducting naturalistic and survey-based studies characterising psychological, social and therapeutic effects of ayahuasca and other psychedelic practices, and for examining practitioner behaviour and treatment-access issues in the psychedelic field.
Collaboration Network
14 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Jordan Aday's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Jordan Aday is associated with.
University of Michigan
academicThe Michigan Psychedelic Center (M-PsyC) at the University of Michigan Medical Center was launched in 2022 to span the psychedelic research landscape, from foundational discovery to clinical implementation.
View stakeholder →Central Michigan University
Central Michigan University (CMU) is a public research university located in Mount Pleasant, Michigan. It offers undergraduate, graduate, and professional programs on its main campus, regional sites, and through online delivery.
View stakeholder →Drug Science
Drug Science is a UK-based independent, science-led drugs charity founded in 2010 and headquartered in London, with work aimed at the UK public and international audiences. It focuses on building an evidence base for drug harms and benefits, and on equipping the public, media, and policymakers with scientific information to support sensible drug laws and evidence-based debate. In psychedelics, Drug Science is an explicit field actor rather than a peripheral observer. Its Medical Psychedelics Working Group promotes evidence-based psychedelic research and access, including support for removing psychedelic drugs from Schedule 1 restrictions, improving regulatory pathways for medical use, and producing educational resources for healthcare professionals and the public. The organization also publishes commentary and research-led content on psychedelic policy, clinical development, and public attitudes, and has recent documented activity around psilocybin regulation, psychedelic terminology, and UK research ecosystem updates.
View stakeholder →